Mesothelioma Dream Study, A Phase Ii Trial Of Nivolumab With Chemotherapy Followed By Maintenance Nivolumab In Patients With Pleural Mesothelioma After Surgery The Nicita Study Protocol Sciencedirect

In october the journal of thoracic oncology published the results of the dream study which was testing the efficacy safety and tolerability of durvalumab combined with the standard chemotherapy treatment for patients diagnosed with pleural mesothelioma.

Meyer ranch park trail map. A phase ii study of durvalumab with first line chemotherapy in mesotheliomafirst results. The aptly named dream study coming out of australia is one of the first of its kind in mesothelioma and so far its results look very promising. Study design and participants.

We had ten sites open and we recruited 54 patients in 10 months which was 8 months ahead of schedule. Nowak and others published dream. Dream was a phase ii trial of durvalumab and chemotherapy in malignant pleural mesothelioma.

In their concluding remarks the study authors noted that the dream trial met its criteria for activity and safety showing that the combination of durvalumab and chemotherapy for mesothelioma. Two thirds of the participants in the study will be randomly assigned to also receive a new treatment called durvalumab. Request pdf on may 20 2018 anna k.

Dream was a multicentre single arm open label phase 2 trial with a safety run in done in nine hospitals in australia appendix p 7. All participants in the study will receive standard first line chemotherapy for mesothelioma. Durvalumab with first line chemotherapy in previously untreated malignant pleural mesothelioma dream.

These were untreated patients so first line and the study was a phase ii multi centre study in australia. Durvalumab is an antibody a type of human. Anz clinical trial registry number.

Dream was a multicentre single arm open label phase 2 trial done in nine hospitals in australia. Weve recently seen that combining chemotherapy and immunotherapy can help people with lung cancer live longer said the principal investigator of the study anna nowak md phd of the. A multicentre single arm phase 2 trial with a safety run in lancet oncol.

Eligible patients were aged 18 years or older and had histologically confirmed malignant pleural mesothelioma considered unsuitable for cancer directed surgery an eastern cooperative oncology group performance status of 0 or 1 and measurable disease as per the modified response evaluation. Find read and cite all the. Dream is an open label single arm multi centre phase ii trial with a safety run in designed to determine the activity safety and tolerability of durvalumab combined with cisplatin and pemetrexed as first line therapy in malignant pleural mesothelioma mpm.

Participants were adults aged 18 years or older with histologically confirmed malignant pleural mesothelioma considered unsuitable for cancer directed surgery and had not.